• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Forward Pharma A/S

    12/29/22 4:04:53 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FWP alert in real time by email
    SC 13G 1 d408900dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

     

     

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c)

    and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

    Under the Securities Exchange Act of 1934

     

     

    Forward Pharma A/S

    (Name of Issuer)

    Ordinary shares, nominal value 0.01 DKK

    (Title of Class of Securities)

    34986J204

    (CUSIP Number)

    December 19, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 34986J204

     

      1.    

      Names of Reporting Persons

     

      StepStone Group LP

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      13,709,598*

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      13,709,598*

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      13,709,598*

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      13.8%*

    12.  

      Type of Reporting Person (See Instructions)

     

      PN; IA

     

    *

    Beneficial ownership percentage is based upon 99,276,587 ordinary shares, nominal value 0.01 DKK (“Ordinary Shares”), of Forward Pharma A/S, a Delaware corporation (the “Company”), issued and outstanding as of May 5, 2022, based on information disclosed in the Company’s notice of general meeting, filed with the Securities and Exchange Commission on May 5, 2022. This statement relates to American Depositary Shares (the “ADS Shares”) beneficially owned by the reporting person, each representing fourteen (14) Ordinary Shares of the Company.

     

    2


    CUSIP No. 34986J204

     

      1.    

      Names of Reporting Persons

     

      StepStone International Investors II, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      12,279,890*

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      12,279,890*

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      12,279,890*

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      12.4%*

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    *

    Beneficial ownership percentage is based upon 99,276,587 Ordinary Shares issued and outstanding as of May 5, 2022. This statement relates to ADS Shares beneficially owned by the reporting person.

     

    3


    CUSIP No. 34986J204

     

      1.    

      Names of Reporting Persons

     

      StepStone International Investors II-G, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      1,429,718*

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      1,429,718*

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,429,718*

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      1.4%*

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    *

    Beneficial ownership percentage is based upon 99,276,587 Ordinary Shares issued and outstanding as of May 5, 2022. This statement relates to ADS Shares beneficially owned by the reporting person.

     

    4


    CUSIP No. 34986J204

     

      1.    

      Names of Reporting Persons

     

      StepStone GC GP, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      13,709,598*

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      13,709,598*

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      13,709,598*

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      13.8%*

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    *

    Beneficial ownership percentage is based upon 99,276,587 Ordinary Shares issued and outstanding as of May 5, 2022. This statement relates to ADS Shares beneficially owned by the reporting person.

     

    5


    Item 1.   

                    (a)   

    Name of Issuer:

     

    Forward Pharma A/S (the “Company”)

       (b)   

    Address of Issuer’s Principal Executive Offices:

     

    Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark

    Item 2.   

       (a)   

    Name of Persons Filing:

     

    StepStone Group LP

    StepStone International Investors II, L.P.

    StepStone International Investors II-G, L.P.

    StepStone GC GP, LLC (collectively, the “StepStone Entities”)

       (b)   

    Address of Principal Business Office or, if none, Residence:

     

    For each of the StepStone Entities:

     

            4225 Executive Square, Suite 1600

            La Jolla, CA 90237

       (c)   

    Citizenship:

     

    StepStone International Investors II, L.P. = Delaware

    StepStone International Investors II-G, L.P. = Delaware

    StepStone GC GP, LLC = Delaware

    StepStone Group LP = Delaware

       (d)   

    Title of Class of Securities:

     

    Ordinary shares, nominal value 0.01 DKK

       (e)   

    CUSIP Number:

     

    34986J204

     

    Item 3.   If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    ☒ Not applicable

                    (a)    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
       (f)    ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
       (g)    ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
       (h)    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
       (k)    ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    6


    Item 4.

    Ownership.

     

                    (a)   

    Amount beneficially owned:

     

    StepStone International Investors II, L.P. (“StepStone II Fund”) has the shared power to vote, direct the voting of, dispose of and direct the disposition of 877,135 ADS Shares, each representing fourteen (14) Ordinary Shares, nominal value 0.01 (“Ordinary Shares”) of the Company. Such ADS Shares represent 12,279,890 Ordinary Shares, which is approximately 12.4% Ordinary Shares outstanding.

     

    StepStone International Investors II-G, L.P. (“StepStone II-G Fund”) has the shared power to vote, direct the voting of, dispose of and direct the disposition of 102,122 ADS Shares, representing 1,429,718 Ordinary Shares, which is approximately 1.4% of Ordinary Shares outstanding.

     

    StepStone GC GP, LLC (“General Partner”) acts as general partner of each of StepStone II Fund and StepStone II-G Fund and, as a result, may be deemed to beneficially own the Ordinary Shares beneficially owned by each of StepStone II Fund and StepStone II-G Fund. As a result, General Partner may be deemed to beneficially own 13,709,598 Ordinary Shares, representing 13.8% of Ordinary Shares outstanding.

     

    StepStone Group LP (“StepStone Group”) acts as the investment manager of each of StepStone II Fund and StepStone II-G Fund and it is the managing member of the General Partner and, as a result, may be deemed to beneficially own the Ordinary Shares beneficially owned by each of StepStone II Fund and StepStone II-G Fund. As a result, StepStone Group may be deemed to beneficially own 13,709,598 Ordinary Shares, representing 13.8% of Ordinary Shares outstanding.

     

    On and after December 19, 2022, StepStone II Fund and StepStone II-G Fund received distributions of ADR Shares of the Issuer from a limited partnership not controlled by the StepStone Entities. This distribution constitutes the entirety of the ownership of the Reporting Persons.

     

       (b)   

    Percent of class:

     

    13.8% (based on 99,276,587 ordinary shares, as reported in the Company’s notice of general meeting filed on May 5, 2022.)

       (c)   

    Number of shares as to which the person has:

          (i)   

    Sole power to vote or to direct the vote

    0

          (ii)   

    Shared power to vote or to direct the vote

    13,709,598 (See Item 4(a))

          (iii)   

    Sole power to dispose or to direct the disposition of

    0

          (iv)   

    Shared power to dispose or to direct the disposition of

    13,709,598 (See Item 4(a))

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    See Item 4(a).

     

    7


    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    8


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: December 29, 2022

     

    STEPSTONE GROUP LP
    By: StepStone Group Holdings LLC, its general partner
    By:   /s/ Jennifer Y. Ishiguro
      Jennifer Y. Ishiguro
      Chief Legal Officer & Secretary
    STEPSTONE GC GP, LLC
    By: StepStone Group LP, its sole member
    By: StepStone Group Holdings LLC, its general partner
    By:   /s/ Jennifer Y. Ishiguro
      Jennifer Y. Ishiguro
      Chief Legal Officer & Secretary
    STEPSTONE INTERNATIONAL INVESTORS II, L.P.
    By: StepStone GC GP, LLC, its general partner
    By: StepStone Group LP, its sole member
    By: StepStone Group Holdings LLC, its general partner
    By:   /s/ Jennifer Y. Ishiguro
      Jennifer Y. Ishiguro
      Chief Legal Officer & Secretary
    STEPSTONE INTERNATIONAL INVESTORS II-G, L.P.
    By: StepStone GC GP, LLC, its general partner
    By: StepStone Group LP, its sole member
    By: StepStone Group Holdings LLC, its general partner
    By:   /s/ Jennifer Y. Ishiguro
      Jennifer Y. Ishiguro
      Chief Legal Officer & Secretary
    Get the next $FWP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FWP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FWP
    SEC Filings

    View All

    SEC Form EFFECT filed by Forward Pharma A/S

    EFFECT - Forward Pharma A/S (0001604924) (Filer)

    1/24/23 12:15:25 AM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Forward Pharma A/S

    POS AM - Forward Pharma A/S (0001604924) (Filer)

    1/20/23 4:40:31 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Forward Pharma A/S

    S-8 POS - Forward Pharma A/S (0001604924) (Filer)

    1/20/23 4:35:43 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

    COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("we" or "Forward"), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"),

    12/19/22 6:00:00 AM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review

    COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("Forward" or the "Company"), today announced that the Enlarged Board of Appeal (the "EBA") of the European Patent Office (the "EPO") has denied Forward's petition for review (the "Petition") of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding ("Opposition Proceeding").The EBA's rejection of the Petition ends the Opposition Proceeding in favor of the opponents and represents an unsuccessful outcome of the Opposition Proceeding, resulting in no royalties being due to the Company from B

    12/6/22 2:00:00 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021

    COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("we," "Forward" or the "Company" and, together with its subsidiaries, the "Group"), today reported consolidated financial results for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was $1.9 million, or $0.02 per share, versus a net loss of $6.4 million, or $0.07 per share, for the year ended December 31, 2020. Our research, development, general and administrative costs increased from $3.4 million for the year ended December 31, 2020 to $3.9 million for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was favorably impacted by a non

    4/8/22 5:25:00 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Forward Pharma A/S (Amendment)

    SC 13G/A - Forward Pharma A/S (0001604924) (Subject)

    2/14/23 4:01:15 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Forward Pharma A/S

    SC 13G - Forward Pharma A/S (0001604924) (Subject)

    12/29/22 4:04:53 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Forward Pharma A/S (Amendment)

    SC 13G/A - Forward Pharma A/S (0001604924) (Subject)

    2/14/22 12:59:14 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care